208 related articles for article (PubMed ID: 35452490)
1. Reconstitution of EBV-directed T cell immunity by adoptive transfer of peptide-stimulated T cells in a patient after allogeneic stem cell transplantation for AITL.
Lammoglia Cobo MF; Ritter J; Gary R; Seitz V; Mautner J; Aigner M; Völkl S; Schaffer S; Moi S; Seegebarth A; Bruns H; Rösler W; Amann K; Büttner-Herold M; Hennig S; Mackensen A; Hummel M; Moosmann A; Gerbitz A
PLoS Pathog; 2022 Apr; 18(4):e1010206. PubMed ID: 35452490
[TBL] [Abstract][Full Text] [Related]
2. Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapy.
Lammoglia Cobo MF; Welters C; Rosenberger L; Leisegang M; Dietze K; Pircher C; Penter L; Gary R; Bullinger L; Takvorian A; Moosmann A; Dornmair K; Blankenstein T; Kammertöns T; Gerbitz A; Hansmann L
Cytotherapy; 2022 Aug; 24(8):818-826. PubMed ID: 35525797
[TBL] [Abstract][Full Text] [Related]
3. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
Icheva V; Kayser S; Wolff D; Tuve S; Kyzirakos C; Bethge W; Greil J; Albert MH; Schwinger W; Nathrath M; Schumm M; Stevanovic S; Handgretinger R; Lang P; Feuchtinger T
J Clin Oncol; 2013 Jan; 31(1):39-48. PubMed ID: 23169501
[TBL] [Abstract][Full Text] [Related]
4. Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts.
Gary R; Aigner M; Moi S; Schaffer S; Gottmann A; Maas S; Zimmermann R; Zingsem J; Strobel J; Mackensen A; Mautner J; Moosmann A; Gerbitz A
J Transl Med; 2018 May; 16(1):124. PubMed ID: 29743075
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
6. Non-uniform
Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
Front Immunol; 2019; 10():2489. PubMed ID: 31736946
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
Clave E; Agbalika F; Bajzik V; Peffault de Latour R; Trillard M; Rabian C; Scieux C; Devergie A; Socié G; Ribaud P; Adès L; Ferry C; Gluckman E; Charron D; Esperou H; Toubert A; Moins-Teisserenc H
Transplantation; 2004 Jan; 77(1):76-84. PubMed ID: 14724439
[TBL] [Abstract][Full Text] [Related]
8. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation.
Marshall NA; Howe JG; Formica R; Krause D; Wagner JE; Berliner N; Crouch J; Pilip I; Cooper D; Blazar BR; Seropian S; Pamer EG
Blood; 2000 Oct; 96(8):2814-21. PubMed ID: 11023516
[TBL] [Abstract][Full Text] [Related]
9. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
[TBL] [Abstract][Full Text] [Related]
10. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
[TBL] [Abstract][Full Text] [Related]
12. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
13. Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis.
Silins SL; Cross SM; Elliott SL; Pye SJ; Burrows SR; Burrows JM; Moss DJ; Argaet VP; Misko IS
J Exp Med; 1996 Nov; 184(5):1815-24. PubMed ID: 8920869
[TBL] [Abstract][Full Text] [Related]
14. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.
Moosmann A; Bigalke I; Tischer J; Schirrmann L; Kasten J; Tippmer S; Leeping M; Prevalsek D; Jaeger G; Ledderose G; Mautner J; Hammerschmidt W; Schendel DJ; Kolb HJ
Blood; 2010 Apr; 115(14):2960-70. PubMed ID: 20103780
[TBL] [Abstract][Full Text] [Related]
15. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution.
Annels NE; Kalpoe JS; Bredius RG; Claas EC; Kroes AC; Hislop AD; van Baarle D; Egeler RM; van Tol MJ; Lankester AC
Clin Infect Dis; 2006 Jun; 42(12):1743-8. PubMed ID: 16705581
[TBL] [Abstract][Full Text] [Related]
16. Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation.
Zhou L; Lu DP
Virol J; 2019 Feb; 16(1):19. PubMed ID: 30736814
[TBL] [Abstract][Full Text] [Related]
17. Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders.
McLaughlin LP; Bollard CM; Keller MD
Front Immunol; 2018; 9():556. PubMed ID: 29616044
[TBL] [Abstract][Full Text] [Related]
18. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2020; 11():1804. PubMed ID: 32973756
[TBL] [Abstract][Full Text] [Related]
19. Human CD8+ memory and EBV-specific T cells show low alloreactivity in vitro and in CD34+ stem cell-engrafted NOD/SCID/IL-2Rγc null mice.
Thomas S; Klobuch S; Sommer M; van Ewijk R; Theobald M; Meyer RG; Herr W
Exp Hematol; 2014 Jan; 42(1):28-38.e1-2. PubMed ID: 24120693
[TBL] [Abstract][Full Text] [Related]
20. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
